Clarity Pharmaceuticals Accelerates Prostate Cancer Trials with FDA Fast Track and $111M Cash

• SECURE trial cohort 4 shows significant PSA reductions with 67Cu-SAR-bisPSMA therapy
• FDA awards Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence prostate cancer
• Strong cash position of $111.2 million supports operations through mid-2026
• Phase III registrational trials CLARIFY and AMPLIFY advancing with positive FDA feedback